Last updated: September 8, 2026
APG-115, also known as alrizomadlin, is an oral small-molecule antagonist of MDM2, the principal negative regulator of tumor-suppressor protein p53. Ascentage Pharma is developing the drug primarily in combination with immune checkpoint inhibitors and other anticancer agents. As of June 2024, APG-115 had not received FDA approval, had no commercial revenue, and remained a clinical-stage asset. Its value depends on proving activity in p53-wild-type cancers, particularly in patients who have progressed on PD-1 or PD-L1 therapy.
The most credible commercial path is a biomarker-defined oncology indication rather than an all-comer solid-tumor label. The main risks are class-wide toxicity, competition from other MDM2 inhibitors, uncertain differentiation from combination immunotherapy, and the difficulty of establishing benefit in heavily pretreated patients.
What is APG-115 and how does it work?
APG-115 is an oral MDM2-p53 pathway inhibitor developed by Ascentage Pharma. MDM2 binds to p53 and promotes its degradation. Blocking MDM2 can increase p53 activity, allowing tumor cells with intact but suppressed p53 signaling to undergo cell-cycle arrest or apoptosis.
The drug is most relevant to tumors retaining wild-type TP53. Tumors with mutant or deleted TP53 may be less responsive because MDM2 inhibition cannot restore a functional p53 response.
| Attribute |
APG-115 |
| Generic name |
Alrizomadlin |
| Development code |
APG-115 |
| Mechanism |
Oral MDM2-p53 antagonist |
| Developer |
Ascentage Pharma |
| Modality |
Small molecule |
| Primary development strategy |
Combination therapy |
| Key partner in clinical development |
Pembrolizumab in selected studies |
| Main target diseases |
Advanced solid tumors, melanoma, hematologic malignancies |
| FDA approval |
None as of June 2024 |
| Orange Book listing |
None because the product is not approved |
| Commercial sales |
None reported |
What is the current clinical development status of APG-115?
APG-115 has advanced beyond initial dose-finding work, but the publicly visible program remained mid-stage rather than registration-ready as of June 2024. The best-developed clinical strategy has been combination treatment with pembrolizumab in advanced solid tumors.
A key study has evaluated APG-115 with pembrolizumab in patients with advanced solid tumors, including patients previously exposed to checkpoint inhibitors. The rationale is that p53 pathway activation may increase tumor immunogenicity and improve immune-mediated tumor killing. Ascentage has reported activity in selected solid-tumor populations, including melanoma, but public disclosures had not established a definitive registrational dataset.
APG-115 clinical development timeline
| Period |
Development event |
| 2016-2018 |
Early clinical development and dose-escalation work began in advanced malignancies |
| 2018 |
ClinicalTrials.gov-listed studies evaluated APG-115 as monotherapy and in combination with pembrolizumab |
| 2019-2022 |
Development expanded into solid tumors and hematologic malignancies |
| 2022-2024 |
Combination studies and disease-specific development continued, with emphasis on melanoma and other advanced cancers |
| June 2024 |
No FDA approval or publicly disclosed pivotal approval application |
Clinical development has included several disease areas rather than a single focused registration program. That approach can create optionality, but it also spreads resources across indications and makes it harder to identify the highest-probability commercial route.
Which cancers are being targeted by APG-115?
The principal opportunity is in advanced tumors where p53 remains functional and standard therapies have failed. Public development materials have associated APG-115 with:
- Melanoma, including patients previously treated with PD-1 or PD-L1 inhibitors
- Other advanced solid tumors treated with pembrolizumab
- Acute myeloid leukemia and related hematologic malignancies
- Potential combinations with venetoclax or other targeted agents
Melanoma is commercially attractive because checkpoint inhibitors are established standards of care and the post-PD-1 population has a meaningful unmet need. The market is also competitive, with approved therapies and numerous investigational combinations.
AML could provide a separate opportunity, but the development and regulatory requirements are different. Combination activity in AML does not automatically support a solid-tumor approval. A successful AML program would likely require clear evidence of response durability, tolerability in older patients, and compatibility with existing backbone therapies.
How effective is APG-115 in clinical studies?
Publicly disclosed results indicate that APG-115 has shown antitumor activity in selected patients, especially when combined with pembrolizumab. The evidence supports continued development but does not establish approval probability.
The most important efficacy questions are:
- Whether responses exceed the activity expected from pembrolizumab or later-line treatment alone.
- Whether benefit is concentrated in TP53-wild-type tumors.
- Whether responses are durable enough to support a meaningful clinical benefit.
- Whether the combination works after prior checkpoint inhibitor failure.
- Whether a reproducible biomarker can identify responsive patients.
MDM2 inhibition can produce hematologic toxicity, gastrointestinal adverse events, fatigue, and laboratory abnormalities. Combination treatment may increase treatment interruptions and dose reductions. The commercial value of APG-115 will depend on maintaining a tolerable dose while demonstrating incremental benefit over available immunotherapy combinations.
What is the FDA regulatory status of APG-115?
APG-115 was not FDA-approved as of June 2024. No publicly confirmed New Drug Application approval or biologics license application applies to the product. Because it is an unapproved small molecule, it has no FDA Orange Book listing and no FDA-recognized approved labeling.
There was no public basis as of the cutoff date to treat APG-115 as having obtained a U.S. Breakthrough Therapy designation or a priority-review approval pathway. FDA designations can change during development, but a designation would not remove the need for controlled efficacy and safety evidence.
The likely regulatory routes are:
| Route |
Relevance to APG-115 |
| Traditional approval |
Most likely route if a randomized study demonstrates clinical benefit |
| Accelerated approval |
Possible if an early endpoint predicts benefit and confirmatory evidence is feasible |
| Orphan drug pathway |
Potentially relevant for narrow hematologic indications, subject to FDA designation |
| Breakthrough Therapy designation |
Would require substantial preliminary evidence in a serious disease |
| Companion diagnostic |
Possible if TP53 status or another biomarker becomes central to patient selection |
What patents protect APG-115 and when could exclusivity end?
APG-115 is protected through a combination of composition-of-matter, pharmaceutical-composition, therapeutic-use, and potentially manufacturing patent families. The public commercial record does not establish one definitive U.S. patent expiration date for the entire APG-115 estate.
For a small molecule, the composition-of-matter patent is usually the most valuable asset. Its effective life depends on the earliest nonprovisional filing date, patent-term adjustment, patent-term extension, terminal disclaimers, and the scope of issued claims. Later formulation and method-of-use patents may extend enforcement leverage but generally do not replicate the commercial value of a strong composition patent.
| IP category |
Strategic role |
| Composition of matter |
Core protection for the active molecule |
| Salt, polymorph, or crystal form |
Can protect physical forms used in manufacturing |
| Pharmaceutical composition |
Covers dosage forms and excipient combinations |
| Method of treatment |
Protects use in specific cancers or biomarker populations |
| Combination therapy |
May cover APG-115 with pembrolizumab or other agents |
| Manufacturing process |
Can raise process-development and substitution barriers |
| Pediatric extension |
Potential additional six months if statutory requirements are met |
| Patent-term extension |
Potentially available after approval for qualifying patents |
Because APG-115 has not been approved, no Orange Book patent listing or patent-term extension applies as of June 2024. Generic companies cannot launch through an Abbreviated New Drug Application until an approved reference product exists.
Are there Paragraph IV challenges or patent litigation involving APG-115?
No publicly established Paragraph IV challenge or U.S. generic patent litigation was associated with APG-115 as of June 2024. That result is expected for an unapproved clinical-stage product.
The more immediate legal risks are not generic litigation. They include:
- Patent opposition or invalidity actions in major jurisdictions
- Competing MDM2 inhibitor patents
- Freedom-to-operate disputes around combination treatment
- Inventorship and ownership issues
- Licensing or collaboration rights covering particular regions
- Patent-term differences between China, the United States, Europe, and Japan
APG-115’s litigation profile should remain limited until the product approaches approval or a competitor establishes a commercially viable MDM2 inhibitor.
How strong is the APG-115 patent estate?
The estate is strategically valuable if the core compound claims remain valid and enforceable in the United States, Europe, China, and other oncology markets. Its strength cannot be measured solely by the number of published applications.
The most important indicators are:
- Whether composition claims cover APG-115 itself rather than only broad Markush structures
- Whether issued claims survive novelty and obviousness challenges
- Whether key jurisdictions granted claims with commercially meaningful scope
- Whether formulation and combination patents have independent value
- Whether competitors can design around the compound or treatment regimen
- Whether the earliest core patent filing leaves adequate post-approval life
A narrow biomarker-based label could increase the value of method-of-use patents but would reduce the addressable patient population. A broad label would improve market potential while increasing the likelihood of competing patents and invalidity challenges.
What licensing deals and partnerships affect APG-115?
Ascentage Pharma is the principal disclosed developer of APG-115. The clinical program has used pembrolizumab in combination studies, but that does not by itself establish a commercial co-development or royalty-sharing agreement with Merck.
The strategic value of APG-115 would increase materially if Ascentage secures a regional licensing transaction with a large oncology company. Such a transaction could provide:
- Funding for randomized trials
- U.S. and European regulatory expertise
- Commercial access to melanoma and hematology prescribers
- Manufacturing scale
- Combination access to marketed immune or targeted therapies
As of June 2024, APG-115 had not generated a publicly disclosed major global commercialization deal comparable to the transactions associated with approved oncology products.
How large is the potential APG-115 market?
The commercial market depends on the eventual label. A broad solid-tumor label could theoretically produce a multibillion-dollar opportunity, but that outcome is unlikely without strong randomized data and a clear predictive biomarker. A focused post-checkpoint melanoma indication would be smaller but more achievable.
Scenario-based market projection
The following estimates represent potential annual worldwide net sales after approval, not current revenue. They are scenario ranges based on possible labels, pricing, adoption, and competition.
| Scenario |
Indicative label |
Peak annual sales |
Probability-adjusted strategic view |
| Low |
Limited later-line combination use in melanoma or selected solid tumors |
$50 million-$150 million |
Commercial niche with limited pricing power |
| Base |
Biomarker-defined melanoma or solid-tumor indication plus selected hematology use |
$300 million-$700 million |
Viable specialty oncology product |
| High |
Multiple approved indications with strong post-checkpoint activity |
$1.0 billion-$2.0 billion |
Blockbuster potential, dependent on differentiated efficacy |
| Downside |
Development failure, inadequate therapeutic window, or superior competitor |
$0 |
No commercial product |
A base-case product could reach annual sales of $300 million to $700 million if it obtains a U.S. approval, expands into Europe and China, and demonstrates a benefit in patients with limited post-checkpoint options. The high case requires more than positive response rates. It requires durable progression-free or overall-survival benefit, manageable toxicity, and a label broad enough to support meaningful treatment volume.
How does APG-115 compare with competing MDM2 inhibitors?
APG-115 competes with investigational MDM2 inhibitors rather than an established approved drug in the same class. Relevant competitors have included milademetan from Syndax, brigimadlin from Boehringer Ingelheim, navtemadlin from Kartos Therapeutics, and idasanutlin from Roche.
| Drug |
Developer |
Development profile as of June 2024 |
Competitive implication |
| APG-115 |
Ascentage Pharma |
Combination-focused development |
Needs proof of differentiated activity and tolerability |
| Milademetan |
Syndax |
Development affected by negative pivotal data in dedifferentiated liposarcoma |
Shows the difficulty of broad MDM2 positioning |
| Brigimadlin |
Boehringer Ingelheim |
Advanced clinical development |
Well-funded competitor with substantial trial capacity |
| Navtemadlin |
Kartos Therapeutics |
Development in solid tumors and hematologic disease |
Competes for biomarker-defined patients |
| Idasanutlin |
Roche |
Earlier program produced mixed results |
Demonstrates class-wide development risk |
APG-115’s strongest competitive argument is its combination strategy and potential activity after checkpoint inhibitor exposure. Its weakness is the absence, as of June 2024, of a publicly established pivotal efficacy result that separates it from the broader MDM2 field.
What generic launch risks exist for APG-115?
Generic launch risk is currently remote because APG-115 has no approved reference product. If approval occurs, the timing of generic entry will depend on:
- Remaining composition-patent term
- Orange Book-listed formulation and method-of-use patents
- Regulatory exclusivity
- Patent-term extension
- Generic Paragraph IV filings
- Settlement agreements
- Commercial attractiveness of the indication
For oncology products, a generic may initially target a narrow indication if method-of-use patents are weak or carved out. Combination use can complicate substitution because the generic must match the approved dosage form and prescribing context, while physicians may use the drug under a broader clinical protocol.
Biosimilar risk is not relevant to APG-115 itself because it is a small molecule, not a biologic. The product could still face competition from biosimilars to combination partners such as pembrolizumab if checkpoint therapy becomes cheaper. That would reduce the overall cost of combination treatment and could pressure APG-115 pricing.
What is the investment outlook for APG-115?
APG-115 is a high-risk, option-value oncology asset. Its value is greater than that of a preclinical MDM2 program because clinical dosing, safety, and early activity have been established. It remains materially below the value of a late-stage asset because the registration pathway and commercially differentiated indication were not confirmed as of June 2024.
Key value inflection points are:
- Randomized evidence showing benefit over checkpoint therapy alone.
- Confirmation of activity in PD-1-refractory melanoma.
- A validated TP53 or alternative response biomarker.
- A registrational hematology study.
- A regional or global licensing transaction.
- FDA designation or acceptance of a registration-enabling trial.
- Evidence that toxicity does not prevent sustained combination dosing.
Key Takeaways
- APG-115, or alrizomadlin, is an oral MDM2-p53 antagonist developed by Ascentage Pharma.
- The program remained clinical-stage and unapproved as of June 2024.
- The principal commercial strategy is combination therapy, particularly with pembrolizumab.
- Melanoma and selected hematologic malignancies are the most plausible initial markets.
- No Orange Book listing, Paragraph IV challenge, generic litigation, or commercial sales applied as of the cutoff date.
- Patent value depends primarily on the surviving composition-of-matter claims and their remaining term.
- A reasonable potential peak-sales range is $300 million-$700 million in a successful base case, with a high case above $1 billion requiring multiple indications and clear differentiation.
- The largest risks are class-wide toxicity, uncertain biomarker selection, weak randomized evidence, and competition from other MDM2 inhibitors.
FAQs About APG-115
Is APG-115 approved by the FDA?
No. APG-115 had no FDA approval as of June 2024 and was not listed in the Orange Book.
What is the generic name of APG-115?
The drug is known as alrizomadlin. Its development code is APG-115.
Is APG-115 a checkpoint inhibitor?
No. APG-115 is an MDM2 inhibitor. It has been studied in combination with checkpoint inhibitors such as pembrolizumab.
Does APG-115 require TP53-wild-type tumors?
The biological rationale is strongest in tumors with functional, wild-type p53 signaling. Whether TP53 status will be required for prescribing depends on clinical validation and the eventual regulatory label.
Could APG-115 become a billion-dollar drug?
Yes, but only in a high-success scenario involving durable efficacy, a tolerable combination regimen, multiple approved indications, and expansion across major oncology markets. The base-case commercial outlook is materially lower.
References
- Ascentage Pharma Group International. (2024). Corporate and pipeline information for APG-115/alrizomadlin. https://www.ascentage.com
- ClinicalTrials.gov. (2024). Study of APG-115 in patients with advanced solid tumors. U.S. National Library of Medicine. https://clinicaltrials.gov
- ClinicalTrials.gov. (2024). Clinical studies of alrizomadlin in advanced malignancies. U.S. National Library of Medicine. https://clinicaltrials.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- National Cancer Institute. (2024). p53 and MDM2 pathway research. https://www.cancer.gov
- U.S. Securities and Exchange Commission. (2024). Ascentage Pharma Group International filings. https://www.sec.gov